Britain and America have concluded a key bilateral deal that will guarantee zero duties on UK medicine exports going into the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the public health system. This commitment ensures that import taxes on these crucial products will be held at zero for a period of 36 months.
This deal follows previous warnings to significantly raise tariffs on branded pharmaceutical imports, with figures floated as high as 100%.
"This agreement between the UK bolsters the worldwide climate for innovative medicines and introduces long-overdue equity to American-British medicine commerce," an announcement said.
Commercial Significance
Pharmaceuticals represent one of the the United Kingdom's largest goods shipped to the United States, which is easily the largest destination for major UK drugmakers.
Trade data reveal that in the one-year period prior to September, the UK exported medicines totaling over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that span.
"This guarantee secures employment, boosts funding and sets the stage for the UK to become a global hub for medical research," a government official stated.
Detailed UK Commitments
The pact involves several specific commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be restricted at 15%. In the past, repayments were more than 20%.
Industry Background
The pact comes amid a protracted tension between the sector and the UK government over drug pricing and NHS adoption.
This friction were heightened by arguments that US customers were charged a premium for the same drugs than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the last ten years.
